oleclumab + AZD4635

**oleclumab + AZD4635** is an experimental combination therapy for cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). **AZD4635** is a small molecule antagonist of the adenosine A2A receptor (A2AR), which inhibits the immunosuppressive effects of adenosine in the tumor microenvironment. **Oleclumab** is a monoclonal antibody targeting CD73, an ecto-5'-nucleotidase that catalyzes the conversion of AMP to adenosine, thus reducing adenosine production. By jointly inhibiting both the adenosine A2A receptor and CD73, the combination aims to provide a dual blockade of the immunosuppressive adenosine pathway and thereby enhance antitumor immunity. The combination has been studied in Phase 2 clinical trials in patients with mCRPC but has shown minimal antitumor activity in this setting. Both drugs are being developed by AstraZeneca[1][3][6].